|
Orthologous residues
|
|
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
BL-41 (B lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
inhibition of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
Rac1 (human)
|
|
increase
|
|
|
|
|
|
|
|
Rac1 activation leads to Bad phosphorylation both in vivo and in vitro.
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
apoptosis, inhibited
|
